MECP2 and prostate cancer: The researchers suggested that MeCP2-induced activation of the pro-survival gene Hsp27 in prostate cancer promotes resistance to both oxidative stress-induced and chemotherapy-induced cell death, a phenomenon supporting prostatic tumorigenesis.